Middle East conflict cost escalations
Prolonged Middle East tensions may increase costs for sourcing, logistics, and working capital, with limited ability to pass through.
PIRAMALPHARMA / Q4-FY26 / risks
Keep the risk register visible.
Piramal Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Tariff impact on CDMO business
US tariffs on Indian pharma could affect innovation-related work; management noted multiple mitigation paths but uncertainty remains.
Intangible asset write-offs
A ₹176 crore impairment was taken on R&D intangibles due to changed market conditions; similar write-offs may recur.
Revenue lumpiness from CDMO
CDMO revenue remains H2-weighted, causing quarterly volatility; this pattern is expected to persist in FY27.